Evidence map›Paper›PMID 18633695›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2008

Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.

Matthew L Zierhut, Marc R Gastonguay, Steven W Martin, Paolo Vicini, Pirow J Bekker, Donna Holloway, Philip T Leese, Mark C Peterson

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Matthew L ZierhutDepartment of Bioengineering, University of Washington, Seattle, WA 98195-2255, USA.
Marc R Gastonguay
Steven W Martin
Paolo Vicini
Pirow J Bekker
Donna Holloway
Philip T Leese
Mark C Peterson
Amgen (United States) · USUniversity of Washington · USChemoCentryx (United States) · USIQVIA (United Kingdom) · GBMetrum Research Group (United States) · USPfizer (United Kingdom) · GB

Funding

Resource Facility for Population KineticsP41EB001975 · NIBIB · UNIVERSITY OF WASHINGTON · PI FOSTER, DAVID M · 2003 to 2007
$4.9M
NIBIB NIH HHS P41 EB-001975
6 · The paper itself

Abstract

Osteoporosis is a metabolic bone disease resulting from increased bone resorption and characterized by low bone mass that leads to increased bone fragility and risk of fracture, particularly of the hip, spine and wrist. Bone resorption is dependent on receptor activator of NF-kappa B ligand (RANKL), which binds to RANK receptor on preosteoclasts to initiate osteoclastogenesis and maintains osteoclast function and survival. To neutralize the effects of RANKL, the body naturally produces the protein osteoprotegerin (OPG), which acts as a decoy receptor for RANKL and contributes to bone homeostasis. We describe the piecewise development of a three-compartment pharmacokinetic model with both linear and Michaelis-Menten eliminations, and an indirect pharmacodynamic response model to describe the pharmacokinetics and pharmacodynamics, respectively, of the fusion protein, Fc-osteoprotegerin (Fc-OPG), in healthy postmenopausal women. Subsequently, model verification was performed and used to address study design questions via simulation. The model was developed using data from eight cohorts (n = 13 subjects/cohort; Fc-OPG:placebo = 10:3) classified by dose level (0.1, 0.3, 1.0, or 3.0 mg/kg) and route of administration (intravenous [IV] or subcutaneous [SC]). Fc-OPG serum concentrations and urinary N-telopeptide/creatinine ratios (NTX) following both IV and SC administration were available. The model provided an adequate fit to the observed data and physiologically plausible parameter estimates. Model robustness was tested via a posterior predictive check with the model performing well in most cases. Subsequent clinical trial simulations demonstrated that a single 3.0-mg/kg SC dose of Fc-OPG would be expected to produce, at 14 days post-dose, a median NTX percentage change from baseline of -45% (with a 95% prediction interval ranging from -34% to -60%). Lastly, model ruggedness was evaluated using local and global sensitivity analysis methods. In conclusion, the model selection and simulation strategies we applied were rigorous, useful, and easily generalizable.

Indexed as

AlgorithmsBayes TheoremBone Density Conservation AgentsCohort StudiesCollagen Type IComputer SimulationCreatinineFemaleHumansImmunoglobulin Fc FragmentsInjections, IntravenousInjections, SubcutaneousMiddle AgedModels, StatisticalOsteoprotegerinPeptidesBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptideCreatinineImmunoglobulin Fc FragmentsOsteoprotegerinPeptides

Identifiers

PMID18633695
OpenAlexW1971267281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.